Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ligand Pharmaceuticals

    NASDAQ: LGND · Real-Time Price · USD
    114.78
    2.28 (2.03%)
    At close: Jun 16, 2025, 3:59 PM
    113.40
    -1.20%
    Pre-market: Jun 17, 2025, 04:30 AM EDT

    Ligand Pharmaceuticals Statistics

    Share Statistics

    Ligand Pharmaceuticals has 19.29M shares outstanding. The number of shares has increased by 7.19% in one year.

    Shares Outstanding

    n/a
    		 19.29M

    Shares Change (YoY)

    n/a
    		 7.19%

    Shares Change (QoQ)

    n/a
    		 1.91%

    Owned by Institutions (%)

    n/a
    		 98.98%

    Shares Floating

    n/a
    		 18.8M

    Failed to Deliver (FTD) Shares

    n/a
    		 506

    FTD / Avg. Volume

    n/a
    		 0.42%

    Short Selling Information

    The latest short interest is 1.23M, so 6.37% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.23M

    Short % of Shares Out

    n/a
    		 6.37%

    Short % of Float

    n/a
    		 7.72%

    Short Ratio (days to cover)

    n/a
    		 11.48

    Valuation Ratios

    The PE ratio is -486.05 and the forward PE ratio is 16.13. Ligand Pharmaceuticals's PEG ratio is 4.53.

    PE Ratio

    n/a
    		 -486.05

    Forward PE

    n/a
    		 16.13

    PS Ratio

    n/a
    		 11.73

    Forward PS

    n/a
    		 6.1

    PB Ratio

    n/a
    		 2.36

    P/FCF Ratio

    n/a
    		 20.58

    PEG Ratio

    n/a
    		 4.53
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Ligand Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 8.93

    Quick Ratio

    n/a
    		 8.55

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 0.17

    Debt / FCF

    n/a
    		 0.07

    Interest Coverage

    n/a
    		 -7.44

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $2,457,838.24

    Profits Per Employee

    n/a
    		 $-59,294.12

    Employee Count

    n/a
    		 68

    Asset Turnover

    n/a
    		 0.18

    Inventory Turnover

    n/a
    		 0.78

    Taxes

    Income Tax

    n/a
    		 6.55M

    Effective Tax Rate

    n/a
    		 260.13%

    Stock Price Statistics

    The stock price has increased by 42.34% in the last 52 weeks. The beta is 0.71, so Ligand Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.71

    52-Week Price Change

    n/a
    		 42.34%

    50-Day Moving Average

    n/a
    		 105.53

    200-Day Moving Average

    n/a
    		 109.85

    Relative Strength Index (RSI)

    n/a
    		 67.54

    Average Volume (20 Days)

    n/a
    		 119,060

    Income Statement

    In the last 12 months, Ligand Pharmaceuticals had revenue of 167.13M and earned -4.03M in profits. Earnings per share was -0.22.

    Revenue

    n/a
    		 167.13M

    Gross Profit

    n/a
    		 156.06M

    Operating Income

    n/a
    		 -22.61M

    Net Income

    n/a
    		 -4.03M

    EBITDA

    n/a
    		 40.79M

    EBIT

    n/a
    		 5.55M

    Earnings Per Share (EPS)

    n/a
    		 -0.22
    Full Income Statement

    Balance Sheet

    The company has 72.31M in cash and 7.11M in debt, giving a net cash position of 65.2M.

    Cash & Cash Equivalents

    n/a
    		 72.31M

    Total Debt

    n/a
    		 7.11M

    Net Cash

    n/a
    		 65.2M

    Retained Earnings

    n/a
    		 498.98M

    Total Assets

    n/a
    		 905.43M

    Working Capital

    n/a
    		 250.63M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 97.05M and capital expenditures -1.82M, giving a free cash flow of 95.23M.

    Operating Cash Flow

    n/a
    		 97.05M

    Capital Expenditures

    n/a
    		 -1.82M

    Free Cash Flow

    n/a
    		 95.23M

    FCF Per Share

    n/a
    		 5.21
    Full Cash Flow Statement

    Margins

    Gross margin is 93.37%, with operating and profit margins of -13.53% and -2.41%.

    Gross Margin

    n/a
    		 93.37%

    Operating Margin

    n/a
    		 -13.53%

    Pretax Margin

    n/a
    		 1.51%

    Profit Margin

    n/a
    		 -2.41%

    EBITDA Margin

    n/a
    		 24.41%

    EBIT Margin

    n/a
    		 -13.53%

    FCF Margin

    n/a
    		 56.98%

    Dividends & Yields

    LGND does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for LGND is $143, which is 24.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $143

    Price Target Difference

    n/a
    		 24.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Nov 2, 2022. It was a forward split with a ratio of 1603:1000.

    Last Split Date

    n/a
    		 Nov 2, 2022

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 1603:1000

    Scores

    Altman Z-Score

    n/a
    		 11.28

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist